<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="publisher-id">GRP</journal-id><journal-title-group><journal-title>Gastroenterology Research and Practice</journal-title></journal-title-group><issn pub-type="ppub">1687-6121</issn><issn pub-type="epub">1687-630X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4452330</article-id><article-id pub-id-type="doi">10.1155/2015/860861</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lafaro</surname><given-names>Kelly J.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cosgrove</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Geschwind</surname><given-names>Jean-Francois H.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kamel</surname><given-names>Ihab</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Herman</surname><given-names>Joseph M.</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pawlik</surname><given-names>Timothy M.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor2">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA</aff><aff id="I2"><sup>2</sup>Department of Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, USA</aff><aff id="I3"><sup>3</sup>Department of Radiology, Johns Hopkins Hospital, Baltimore, MD 21287, USA</aff><aff id="I4"><sup>4</sup>Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, USA</aff><author-notes><corresp id="cor1">*Kelly J. Lafaro: <email>klafaro@gmail.com</email> and </corresp><corresp id="cor2">*Timothy M. Pawlik: <email>tpawlik1@jhmi.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Massimo Pancione </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>19</day><month>5</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>860861</elocation-id><history><date date-type="received"><day>9</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2015 Kelly J. Lafaro et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Cholangiocarcinoma is a highly fatal primary cancer of the bile ducts which arises from malignant transformation of bile duct epithelium. </plain></SENT>
<SENT sid="3" pm="."><plain>While being an uncommon malignancy with an annual incidence in the United States of 5000 new cases, the incidence has been increasing over the past 30 years and comprises 3% of all gastrointestinal cancers. </plain></SENT>
<SENT sid="4" pm="."><plain>Cholangiocarcinoma can be classified into intrahepatic (ICC) and extrahepatic (including hilar and distal bile duct) according to its anatomic location within the biliary tree with respect to the liver. </plain></SENT>
<SENT sid="5" pm="."><plain>This paper reviews the management of ICC, focusing on the epidemiology, risk factors, diagnosis, and surgical and nonsurgical management. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="6" pm="."><plain>1. </plain></SENT>
<SENT sid="7" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="8" pm="."><plain>Cholangiocarcinoma is a highly fatal primary cancer of the bile ducts that arises from malignant transformation of bile duct epithelium. </plain></SENT>
<SENT sid="9" pm="."><plain>Recent research in mouse models suggests the possibility that cholangiocarcinoma can arise directly from the transdifferentiation of hepatocytes [1, 2]. </plain></SENT>
<SENT sid="10" pm="."><plain>Cholangiocarcinoma can be classified into intrahepatic (ICC) and extrahepatic (including hilar and distal bile duct) according to its anatomic location within the biliary tree with respect to the liver. </plain></SENT>
<SENT sid="11" pm="."><plain>While being an uncommon malignancy with an annual incidence in the United States of 5000 new cases, the incidence of ICC has been increasing over the past 30 years and comprises 3% of all gastrointestinal cancers. </plain></SENT>
<SENT sid="12" pm="."><plain>ICC can arise in patients both with a normal liver and with underlying chronic liver disease [3]. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2"><title><text><SENT sid="13" pm="."><plain>2. </plain></SENT>
<SENT sid="14" pm="."><plain>Epidemiology </plain></SENT>
</text></title><p><text><SENT sid="15" pm="."><plain>ICC accounts for 10–15% of all primary liver cancers worldwide and is the second most common primary liver malignancy after hepatocellular carcinoma with a varying incidence worldwide. </plain></SENT>
<SENT sid="16" pm="."><plain>The highest recorded incidence is in Thailand (&gt;80/100,000 population) [4] whereas there is a much lower incidence in the Western world (US: 1.67/100,000 and Canada: 0.35/100,000) [3, 4]. </plain></SENT>
<SENT sid="17" pm="."><plain>The global incidence of ICC has been increasing [5]. </plain></SENT>
<SENT sid="18" pm="."><plain>For example, the estimated age-adjusted incidence of ICC in the United States increased by 165% from 1979 to 1999 (from 0.32 per 100,000 in 1975 to 1979 to 0.85 per 100,000 in 1995 to 1999), with a majority of the increase observed after 1985 [6]. </plain></SENT>
<SENT sid="19" pm="."><plain>An increase in incidence has also been seen in other countries such as the United Kingdom [7] and Japan [8]. </plain></SENT>
<SENT sid="20" pm="."><plain>Some of this increase in incidence may be attributed to the disease being historically underdiagnosed due to less sophisticated radiologic and endoscopic imaging, as well as misclassification. </plain></SENT>
<SENT sid="21" pm="."><plain>Welzel et al. reported, however, that the increase incidence of ICC was a “real” phenomenon even when taking into account previous misclassification [9]. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>In addition to a rising incidence, an increase in mortality rates from ICC has also been reported in the US, UK, Italy, and Germany. </plain></SENT>
<SENT sid="23" pm="."><plain>A study in the US found an increase in mortality rates in ICC between 1973 and 1997 with an estimated annual percent change of 9.4% [10]. </plain></SENT>
<SENT sid="24" pm="."><plain>A different study in the UK reported a 15-fold increase in age specific mortality rates (from 0.1 to 1.5/100,000 population) between 1968 and 1996 [11]. </plain></SENT>
<SENT sid="25" pm="."><plain>Mortality from ICC tripled in Germany between 1998 and 2008 [12]. </plain></SENT>
<SENT sid="26" pm="."><plain>Italy noted an even more dramatic increase in mortality rates between1980 and 2003, reporting an increase from 0.2 to 5.9/million [13]. </plain></SENT>
</text></p></sec><sec id="sec3"><title><text><SENT sid="27" pm="."><plain>3. </plain></SENT>
<SENT sid="28" pm="."><plain>Risk Factors </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>There are several risk factors associated with ICC and the development of disease is likely multifactorial. </plain></SENT>
<SENT sid="30" pm="."><plain>The risk of ICC increases with older age as well as female sex. </plain></SENT>
<SENT sid="31" pm="."><plain>In addition, several other risk factors include primary sclerosing cholangitis, hepatolithiasis, choledochal cysts, primary biliary cirrhosis, parasitic biliary infection with Clonorchis sinensis or Opisthorchis viverrini, inflammatory bowel disease, and chronic pancreatitis [14], as well as the historical use of the radiologic contrast agent Thorotrast. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>More recently, several risk factors that have traditionally been considered risk factors for hepatocellular carcinoma (HCC) such as alcoholic liver disease [14], obesity [15], diabetes [14, 16], cirrhosis, hepatitis B infection [15, 17, 18], and tobacco use [14] have been implicated in ICC [15]. </plain></SENT>
<SENT sid="33" pm="."><plain>Studies from Korea, Japan, Italy, US, and Denmark have all reported cirrhosis, without distinction of causation, as a risk factor for ICC [16, 19–22]. </plain></SENT>
<SENT sid="34" pm="."><plain>A 2012 meta-analysis of seven case-control studies with a total study population of 399,608 reported an overall OR of 22.92 (95% CI: 18.24–28.79) for the association between cirrhosis and ICC [15]. </plain></SENT>
<SENT sid="35" pm="."><plain>Of note, with regard to the noted risk factors, there has been no appreciable increase in any specific factor that can fully account for the increase in incidence of ICC over the past 30 years (Table 1). </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>Two risk factors that have increased in incidence worldwide are nonalcoholic fatty liver disease (NAFLD) and hepatitis C. </plain></SENT>
<SENT sid="37" pm="."><plain>The association between ICC and hepatitis C has been demonstrated in the United States in a study by Shaib et al. that noted that hepatitis C virus infection was significantly more prevalent among ICC cases than controls (adjusted odds ratio: 6.1; P &lt; 0.0001) [16]. </plain></SENT>
<SENT sid="38" pm="."><plain>El-Serag et al. similarly reported an increased risk for ICC in the setting of HCV infection (hazard ratio (HR): 2.55; 95% confidence interval (95% CI): 1.31, 4.95) [23]. </plain></SENT>
<SENT sid="39" pm="."><plain>The association between HCV and ICC is not unique to the US. </plain></SENT>
<SENT sid="40" pm="."><plain>In Italy the adjusted increased odds ratio for ICC in the setting of HCV was 9.7 (95% confidence interval (95% CI): 1.6–58.9) [24], while in Japan cumulative rates of newly diagnosed ICC among HCV patients were 1.6% at 5 years and 3.5% at 10 years, which was 1000 times higher than the estimated incidence in the general Japanese population [25]. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>NAFLD, which is associated with obesity and metabolic syndrome, is an increasing concern worldwide and especially in the United States. </plain></SENT>
<SENT sid="42" pm="."><plain>NAFLD can lead to nonalcoholic steatohepatitis (NASH), eventual cirrhosis, and HCC [26]. </plain></SENT>
<SENT sid="43" pm="."><plain>Recently, investigators have looked at these factors in the setting of cholangiocarcinoma. </plain></SENT>
<SENT sid="44" pm="."><plain>Metabolic syndrome was implicated as a risk factor for ICC (odds ratio: 1.56; 95% confidence interval: 1.32–1.83; P &lt; 0.0001) by Welzel et al. who evaluated 743 ICC cases from the SEER database diagnosed between 1993 and 2005 [14]. </plain></SENT>
<SENT sid="45" pm="."><plain>In a separate study from the UK, the authors reported that a BMI &gt;30 kg/m2 was associated with a 1.5 increased risk of cholangiocarcinoma compared with patients who had a BMI &lt;25 kg/m2 (OR: 1.52, 95% CI: 1.03–2.24) [27]. </plain></SENT>
<SENT sid="46" pm="."><plain>This study did not, however, stratify patients by type of cholangiocarcinoma. </plain></SENT>
<SENT sid="47" pm="."><plain>In a different study, Reddy et al. reported that 17.1% of patients who underwent resection for ICC at one of 8 major US hepatobiliary centers had underlying NASH on histology [28]. </plain></SENT>
<SENT sid="48" pm="."><plain>A meta-analysis that combined 3 case-control studies evaluating obesity as a risk factor for ICC found an overall OR of 1.6 [15]. </plain></SENT>
<SENT sid="49" pm="."><plain>While many of these risk factors are relatively common, only a very small percentage of patients with ICC actually have an identifiable risk factor. </plain></SENT>
<SENT sid="50" pm="."><plain>A single institution study of 73 surgical ICC cases found that 48 (66%) of these cases had none of the major risk factors including HBV, HCV, PSC, NASH, or alcohol induced cirrhosis [29]. </plain></SENT>
<SENT sid="51" pm="."><plain>As such, it is likely that there are additional contributing factors to the development of ICC. </plain></SENT>
</text></p></sec><sec id="sec4"><title><text><SENT sid="52" pm="."><plain>4. </plain></SENT>
<SENT sid="53" pm="."><plain>Presentation </plain></SENT>
</text></title><p><text><SENT sid="54" pm="."><plain>While cholangiocarcinoma of the hilum or distal ducts often presents with biliary obstruction, ICC is often an incidental radiologic finding. </plain></SENT>
<SENT sid="55" pm="."><plain>Thus, clinical presentation alone is rarely sufficient for diagnosis. </plain></SENT>
<SENT sid="56" pm="."><plain>At very late stages, patients may develop hepatomegaly, malaise, weight loss, failure to thrive, abdominal pain, night sweats, or jaundice; however, the frequent biliary obstruction seen in hilar or distal lesions is rarely present in ICC. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>Lesions detected on radiologic imaging can be evaluated using bile duct brushings or biopsied using endoscopic ultrasound and fine needle aspiration (EUS-FNA) to distinguish cholangiocarcinomas from hepatocellular carcinoma and metastatic disease. </plain></SENT>
<SENT sid="58" pm="."><plain>While there is a theoretical risk of seeding the needle track while performing the biopsy, a 2013 study by El-Chafic et al. showed that number of needle passes did not have a statistically significant impact on overall survival or progression-free survival [30]. </plain></SENT>
</text></p><p><text><SENT sid="59" pm="."><plain>Many times, these FNA specimens have subsequent pathology revealing “adenocarcinoma.” Due to the fact that most adenocarcinomas of the liver are metastatic in origin, careful pathologic review and immunohistochemistry staining should be attempted to elucidate the origin of the tumor. </plain></SENT>
<SENT sid="60" pm="."><plain>Some immunohistochemical markers, including CK7, CK20, CDX-2, TTF-1, ER, PR, BRST-2, AFP, CEA, CA19-9, and PSA, may help to exclude common primary sites including colon, lung, breast, and prostate [29]. </plain></SENT>
<SENT sid="61" pm="."><plain>ICCs are often positive for CK7, CEA, and CA19-9 and negative for the other markers listed above. </plain></SENT>
<SENT sid="62" pm="."><plain>On histology, ICC can show tubular and/or papillary structures often with a fibrous stroma [31–35]. </plain></SENT>
<SENT sid="63" pm="."><plain>This histologic appearance when diagnosed on a core biopsy of the liver can be very similar to the appearance of metastatic lesions to the liver from extrahepatic adenocarcinomas of the foregut [36]. </plain></SENT>
<SENT sid="64" pm="."><plain>A search to rule out an extrahepatic primary tumor should therefore usually be performed using upper and lower endoscopy to rule out occult gastrointestinal malignancy; in addition, cross-sectional imaging of the chest, abdomen, and pelvis to rule out an intrathoracic or intra-abdominal primary tumor can also be helpful. </plain></SENT>
</text></p><p><text><SENT sid="65" pm="."><plain>In addition to these imaging studies, laboratory values including tumor markers should be assessed (Figure 1). </plain></SENT>
<SENT sid="66" pm="."><plain>Carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and carbohydrate antigen 19-9 (CA19-9) should be obtained. </plain></SENT>
<SENT sid="67" pm="."><plain>While the prognostic value of these tumor markers is not well defined, a small report from the Mayo Clinic evaluating 50 patients found that serum CA19-9 &gt;100 U/mL was associated with a sensitivity of 53% for the diagnosis of cholangiocarcinoma and a specificity of 75–90% [37]. </plain></SENT>
<SENT sid="68" pm="."><plain>In a separate study of 74 patients undergoing surgical resection for ICC, the authors reported that CA 19-9 levels greater than 100 U/mL were independently associated with early recurrence and shorter survival after surgical resection [38]. </plain></SENT>
<SENT sid="69" pm="."><plain>However, it must be noted that biliary obstruction and acute cholangitis may also cause an increase in CA19-9; therefore markers should be measured after biliary decompression and drainage. </plain></SENT>
<SENT sid="70" pm="."><plain>Reports of more specific serum marks such as CYFRA21-1, claudin-4, insulin-like growth factor binding protein 5 (IGFBP-5), and biglycan exist; however, none of these are routinely clinically used [39, 40]. </plain></SENT>
</text></p><sec id="sec4.1"><title><text><SENT sid="71" pm="."><plain>4.1. </plain></SENT>
<SENT sid="72" pm="."><plain>ICC on Cross-Sectional Imaging </plain></SENT>
</text></title><p><text><SENT sid="73" pm="."><plain>ICC is often diagnosed as an incidental radiologic finding on cross-sectional imaging performed for other reasons. </plain></SENT>
<SENT sid="74" pm="."><plain>The radiographic features of classic mass-forming ICC on CT and magnetic resonance imaging (MRI) are well described. </plain></SENT>
<SENT sid="75" pm="."><plain>ICC, however, can often be difficult to diagnose on the basis of radiologic findings alone. </plain></SENT>
<SENT sid="76" pm="."><plain>On MRI, ICC lesions are generally hypointense on T1-weighted images and heterogeneously hyperintense on T2-weighted images with central hypointensity, indicating central tumor fibrosis [41]. </plain></SENT>
<SENT sid="77" pm="."><plain>Lesions can demonstrate initial rim enhancement characterized by progressive and concentric enhancement and pooling of contrast on dynamic contrast-enhanced MRI that again may indicate fibrosis (Figure 2) [41, 42]. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>The appearance of ICC on unenhanced CT scan is often as a hypodense mass with irregular margins [43]. </plain></SENT>
<SENT sid="79" pm="."><plain>On contrast-enhanced helical CT, rim-like enhancement at the tumor periphery is usually seen in both the arterial and portal venous phase with gradual centripetal enhancement on delayed imaging [41, 44]. </plain></SENT>
<SENT sid="80" pm="."><plain>ICC may only enhance completely on delayed imaging obtained after contrast administration, a finding related to the desmoplastic nature of the tumor. </plain></SENT>
<SENT sid="81" pm="."><plain>In one study, delayed contrast-enhanced CT performed in 47 patients with ICC performed 6–36 minutes after contrast administration showed that 74% of tumors had hyperattenuating delayed contrast enhancement [41, 45]. </plain></SENT>
<SENT sid="82" pm="."><plain>While imaging may be helpful, it cannot reliably distinguish between ICC, metastatic adenocarcinoma from extrahepatic primaries or HCC with cirrhosis [46]. </plain></SENT>
</text></p></sec></sec><sec id="sec5"><title><text><SENT sid="83" pm="."><plain>5. </plain></SENT>
<SENT sid="84" pm="."><plain>Staging </plain></SENT>
</text></title><p><text><SENT sid="85" pm="."><plain>Until the most recent 7th edition of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) guidelines that were published in 2010, ICC was staged using criteria for HCC. </plain></SENT>
<SENT sid="86" pm="."><plain>In fact, prior to the 7th edition of AJCC/UICC staging manual, there was no internationally recognized distinct staging system for cholangiocarcinoma [47]. </plain></SENT>
<SENT sid="87" pm="."><plain>Two separate staging systems had, however, been proposed based on data from Japan. </plain></SENT>
<SENT sid="88" pm="."><plain>The first, proposed by Okabayashi et al., was based on the multivariate modeling that found the presence of vascular invasion, multiple tumors, symptomatic disease, and regional lymph node metastasis all to be associated with a worse prognosis [48]. </plain></SENT>
<SENT sid="89" pm="."><plain>Taking these four prognostic factors into account, Okaybayashi et al. proposed a staging system irrespective of tumor size: Stage I: solitary tumor without vascular invasion; Stage II: solitary tumor with the presence of vascular invasion; Stage IIIa: multiple tumors with or without the presence of invasion; Stage IIIb: any tumor with involvement of regional lymph nodes; Stage IV: distant metastases [48]. </plain></SENT>
<SENT sid="90" pm="."><plain>A second staging system, proposed by Yamasaki, used a point system to stratify patients based on size (greater than 2 cm), solitary versus multiple tumors, the presence or absence of peritoneal, portal vein, or hepatic vein invasion [49]. </plain></SENT>
<SENT sid="91" pm="."><plain>Regional lymph node metastasis and distant metastasis were also independently associated with outcome and were therefore included. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>More recently, Nathan et al. evaluated 598 patients who underwent surgery for ICC between 1988 and 2004 from the SEER database and proposed a new simplified staging system from independent predictors of survival that eventually was largely adopted in the 7th edition of the AJCC/UICC staging manual [50]. </plain></SENT>
<SENT sid="93" pm="."><plain>These authors compared the discriminative abilities of the 6th edition of AJCC/UICC staging manual as well as the two previously discussed Japanese studies to the newly proposed staging system. </plain></SENT>
<SENT sid="94" pm="."><plain>The authors noted that the new system had superior discriminatory power. </plain></SENT>
<SENT sid="95" pm="."><plain>In this analysis, the presence of multiple tumors (HR: 1.42, 95% CI: 1.01–2.01) and the presence of vascular invasion (HR: 1.53, 95% CI: 1.10–2.12) were independent predictors of worse prognosis on multivariate analysis [50]. </plain></SENT>
<SENT sid="96" pm="."><plain>Tumor size was not predictive of survival after surgical resection. </plain></SENT>
<SENT sid="97" pm="."><plain>As such, the staging system proposed by Nathan et al. included 3 T stages: T1: solitary tumor of any size without vascular invasion, T2: multiple tumors or any tumor with vascular invasion, and T3: extrahepatic extension [50]. </plain></SENT>
</text></p><p><text><SENT sid="98" pm="."><plain>With the publication of the 7th edition of the AJCC/UICC staging manual in 2010, ICC is now staged using its own distinct criteria and no longer under the same tumor-node-metastasis (TNM) stages of HCC [47]. </plain></SENT>
<SENT sid="99" pm="."><plain>In the current staging system, tumor size was removed as a prognostic factor. </plain></SENT>
<SENT sid="100" pm="."><plain>In this system, “T” classification is based on the number of tumors, vascular invasion, and direct invasion of adjacent structures [47]. </plain></SENT>
<SENT sid="101" pm="."><plain>The T classification is defined as follows: T1: solitary tumors without vascular invasion, T2: multiple tumors (multifocal disease, intrahepatic metastasis, or satellite lesions) and any tumor with vascular invasion, T3: any tumor with direct invasion of adjacent organs, and T4: tumors with any periductal-infiltrating component on histology. </plain></SENT>
<SENT sid="102" pm="."><plain>The “N” and “M” classifications, similar to other solid abdominal tumors, are included with N1 disease considered in any patient with hilar, periduodenal, or peripancreatic regional lymph node metastasis and distant metastasis classified as M1 disease [47] (Table 2). </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>In 2011, the 7th edition of the AJCC/UICC staging system for ICC was independently validated in France. </plain></SENT>
<SENT sid="104" pm="."><plain>The authors noted that the 7th edition of AJCC/UICC was more discriminating in predicting survival compared with the two Japanese classifications or the 5th and 6th editions of the AJCC/UICC staging manual [51]. </plain></SENT>
<SENT sid="105" pm="."><plain>There will undoubtedly be more changes to the ICC system in the upcoming 8th edition of the AJCC/UICC staging manual as more studies more rigorously evaluate the true effect of tumor size, as well as the relative importance of the metastatic lymph nodes in various stations. </plain></SENT>
</text></p></sec><SecTag type="DISCUSS"><sec id="sec6"><title><text><SENT sid="106" pm="."><plain>6. </plain></SENT>
<SENT sid="107" pm="."><plain>Surgical Management of ICC </plain></SENT>
</text></title><p><text><SENT sid="108" pm="."><plain>Complete surgical resection of ICC with negative margins (R0 resection) currently represents the only potentially curative option. </plain></SENT>
<SENT sid="109" pm="."><plain>Because a subset of patients with ICC will have metastatic disease that was not identified on preoperative imaging, some surgeons advocate for a staging laparoscopy prior to laparotomy for resection. </plain></SENT>
<SENT sid="110" pm="."><plain>While data are lacking with respect to the diagnostic yield of staging laparoscopy, there have been reports suggesting a potential role in ICC. </plain></SENT>
<SENT sid="111" pm="."><plain>In a study of 39 patients with potentially resectable ICC, staging laparoscopy identified peritoneal carcinomatosis (11/14) and liver metastases (5/14) in a small subset of patients, thereby avoiding an unnecessary laparotomy in 36% of patients [52]. </plain></SENT>
<SENT sid="112" pm="."><plain>In a second series of 22 patients with potentially resectable ICC, staging laparoscopy detected peritoneal or intrahepatic metastases in 6 (27%) patients [53]. </plain></SENT>
<SENT sid="113" pm="."><plain>Due to the paucity of evidence, staging laparoscopy is not routinely performed for patients with potentially resectable ICC. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>Surgical resection should be offered to all patients who are appropriate surgical candidates with potentially resectable disease. </plain></SENT>
<SENT sid="115" pm="."><plain>Evaluation of SEER data from 1988 to 2003 found, however, that only 37% of patients with localized disease underwent cancer directed surgery [54]. </plain></SENT>
<SENT sid="116" pm="."><plain>While the reasons for which patients did not undergo surgery were not evaluated in the study, the reasons are likely multifactorial. </plain></SENT>
<SENT sid="117" pm="."><plain>ICC often presents as a large, locally advanced tumor that can make surgery technically challenging, often requiring extensive resection to achieve negative margins. </plain></SENT>
<SENT sid="118" pm="."><plain>Sortiropoulos et al. examined 41 R0 ICC resections from 1998 to 2006 and found that 78% required extended hepatectomy and 29% required resection of the hilar bifurcation [55]. </plain></SENT>
<SENT sid="119" pm="."><plain>In addition, partial resection of the diaphragm, bile duct reconstruction, and vascular reconstruction were also noted. </plain></SENT>
<SENT sid="120" pm="."><plain>A second study from Memorial Sloan Kettering Cancer Center noted that only 30% of patients diagnosed with ICC were surgical candidates (n = 82). </plain></SENT>
<SENT sid="121" pm="."><plain>Among the 82 patients who underwent surgical resection for ICC during the 16-year study period, 78% required major hepatectomy with 49% requiring an extended hepatectomy, 20.7% requiring extrahepatic bile duct resection, and 8.5% requiring vascular resection [56]. </plain></SENT>
<SENT sid="122" pm="."><plain>These studies reiterate how extensive resections are often required to obtain R0 margins for of ICC. </plain></SENT>
</text></p><p><text><SENT sid="123" pm="."><plain>The use of routine lymphadenectomy is not well defined in ICC resection. </plain></SENT>
<SENT sid="124" pm="."><plain>While lymphadenectomy is often standard in many Eastern centers, it is not universally performed in many Western countries [57]. </plain></SENT>
<SENT sid="125" pm="."><plain>In the 2009 evaluation of SEER data by Nathan et al., the authors noted that only one-half of the patients who underwent resection for ICC had at least one lymph node examined, and, of these, 32% were found to have metastatic nodal disease [50]. </plain></SENT>
<SENT sid="126" pm="."><plain>A second meta-analysis from the same group analyzed 4756 patients undergoing curative-intent surgical treatment and demonstrated that 34% of patients who underwent lymphadenectomy had lymph node metastasis [58]. </plain></SENT>
<SENT sid="127" pm="."><plain>Some investigators, however, argue that the procedure is unnecessary. </plain></SENT>
<SENT sid="128" pm="."><plain>A retrospective study from Japan which evaluated 68 patients with mass-forming ICC recommended against routine lymphadenectomy as the authors argued that there was survival benefit associated with lymphadenectomy. </plain></SENT>
<SENT sid="129" pm="."><plain>A different retrospective study from China of 124 patients with ICC who underwent surgical resection from 2006 to 2007 similarly showed no survival benefit among patients who underwent lymphadenectomy and had nodal metastasis [59]. </plain></SENT>
<SENT sid="130" pm="."><plain>Lymphadenectomy may, however, be important to accurate stage patients. </plain></SENT>
<SENT sid="131" pm="."><plain>Multiple studies have noted that overall nodal status (N0 versus N1), as well as the number of nodal metastases, strongly predicts prognosis [57, 60]. </plain></SENT>
<SENT sid="132" pm="."><plain>In a study using an international multi-institutional database evaluating 449 patients between 1973 and 2010, 248 (55%) underwent lymphadenectomy and 74 (30%) were found to have lymph node metastasis [60]. </plain></SENT>
<SENT sid="133" pm="."><plain>N1 disease had an adverse effect on overall survival (median survival: N0: 30 months versus N1: 24 months; P = 0.03) [60]. </plain></SENT>
<SENT sid="134" pm="."><plain>A recent retrospective study of 221 patients from Japan similarly reported that lymph node metastasis was a strong, independent prognostic factor of survival (P &lt; 0.001, HR: 2.577, and 95% CI: 1.742–3.813) [61]. </plain></SENT>
<SENT sid="135" pm="."><plain>Given the relative high incidence of patients found to have lymph node metastasis (30%) and the prognostic implications, lymphadenectomy should be strongly considered in patients undergoing surgical resection for ICC. </plain></SENT>
</text></p></sec></SecTag><sec id="sec7"><title><text><SENT sid="136" pm="."><plain>7. </plain></SENT>
<SENT sid="137" pm="."><plain>Outcomes following Surgery </plain></SENT>
</text></title><p><text><SENT sid="138" pm="."><plain>Five-year overall survival following resection for ICC ranges from 14% to 40% when examining data published from 1977 to 2007 [5, 38, 50, 56, 62–74]. </plain></SENT>
<SENT sid="139" pm="."><plain>There does seem to be an improvement in overall 5-year survival documented in the past decade, resulting in a cumulative 34.4% improvement in survival from 1992 to 2002 [38, 62]. </plain></SENT>
<SENT sid="140" pm="."><plain>Data from one high volume center reported an overall 5-year survival of 40% with an increase in 5-year survival, as well as the incidence of R0 resection, when comparing patients who underwent resection from 1973 to 1995 versus those patients who underwent resection from 1996 to 2004 [72]. </plain></SENT>
</text></p><p><text><SENT sid="141" pm="."><plain>A major concern following surgery for ICC is disease recurrence. </plain></SENT>
<SENT sid="142" pm="."><plain>In 2009, Choi et al. reported a 5-year survival of 39.5%, but the median disease-free survival time was only 12.3 months [67]. </plain></SENT>
<SENT sid="143" pm="."><plain>The overall risk of recurrence following resection was 64% with the most common sites of recurrence being the liver (56%) and portal lymph nodes (31%) [67]. </plain></SENT>
<SENT sid="144" pm="."><plain>A different study by Endo et al. reported a disease-free survival of 26 months, with more than 50% of the patients developing recurrence following resection; the liver again was the most common site of recurrence (63%) [56]. </plain></SENT>
<SENT sid="145" pm="."><plain>Upon further analysis, the incidence of recurrence in patients with solitary tumors without lymph node metastases was only 47%, while recurrence among patients with multiple tumors and lymph node metastasis was 93% [56]. </plain></SENT>
<SENT sid="146" pm="."><plain>A larger study of 301 patients who underwent resection for ICC from 1990 to 2011 found a 53.5% recurrence rate with the most common site of recurrence being intrahepatic [75]. </plain></SENT>
<SENT sid="147" pm="."><plain>Macrovascular invasion, lymph node metastasis, and tumor size &gt;5 cm were all independently associated with an increased risk of recurrence. </plain></SENT>
<SENT sid="148" pm="."><plain>Recently, a collaboration between 13 major hepatobiliary centers in the US, Europe, and Asia compiled data from 514 patients who underwent surgical resection for ICC from 1990 to 2011 [76]. </plain></SENT>
<SENT sid="149" pm="."><plain>From these data, a nomogram to predict long-term survival after resection was created using a point system for each of the 6 variables found to be significant including age, tumor size, number of tumors, nodal status, vascular invasion, and cirrhosis. </plain></SENT>
<SENT sid="150" pm="."><plain>Each of these variables was assigned a weighted point score and the higher total score was correlated with a worse prognosis [76]. </plain></SENT>
<SENT sid="151" pm="."><plain>Patients in the lowest quartile had a median survival time of 14.8 months compared with 80.2 months for the patients in the highest quartile [76]. </plain></SENT>
<SENT sid="152" pm="."><plain>The high recurrence rate and general poor long-term prognosis associated with resected ICC reinforce the need for more effective adjuvant therapies. </plain></SENT>
</text></p></sec><SecTag type="DISCUSS"><sec id="sec8"><title><text><SENT sid="153" pm="."><plain>8. </plain></SENT>
<SENT sid="154" pm="."><plain>Nonsurgical Management of ICC </plain></SENT>
</text></title><sec id="sec8.1"><title><text><SENT sid="155" pm="."><plain>8.1. </plain></SENT>
<SENT sid="156" pm="."><plain>Systemic Therapy </plain></SENT>
</text></title><p><text><SENT sid="157" pm="."><plain>A significant proportion of patients diagnosed with ICC are unresectable at the time of diagnosis resulting in a median survival time of 5 to 8 months [5, 77]. </plain></SENT>
<SENT sid="158" pm="."><plain>Randomized, phase three clinical trials examining chemotherapy have been difficult to conduct for ICC likely due to the small number of patients and the heterogeneous nature of biliary tract malignancies. </plain></SENT>
<SENT sid="159" pm="."><plain>Historically, 5-FU was the first chemotherapeutic agent used in unresectable ICC with only a 10% response rate as a single agent [78]. </plain></SENT>
<SENT sid="160" pm="."><plain>In a small study of 90 patients which included pancreatic (53 patients) as well as biliary tract cancers (37 patients), 5-FU, leucovorin, and etoposide therapy showed a significantly longer overall survival time versus best supportive care (median 6 versus 2.5 months; P &lt; 0.01) [79]. </plain></SENT>
<SENT sid="161" pm="."><plain>Chemotherapy for ICC has evolved over time due to multiple small phase 2 studies showing improved response rates of 22%–50% with gemcitabine based combination therapies compared to the traditional response rates of 10%–30% with fluoropyrimidine based chemotherapy regimens [78, 80–84]. </plain></SENT>
<SENT sid="162" pm="."><plain>To date, there have not yet been any trials that separate ICC and ECC. </plain></SENT>
<SENT sid="163" pm="."><plain>In 2010, the Advanced Biliary Cancer- (ABC-) 02 trial was published. </plain></SENT>
<SENT sid="164" pm="."><plain>This was the first phase III, randomized control trial in patients with advanced biliary tract cancer that compared single agent gemcitabine with combination of gemcitabine and cisplatin [85]. </plain></SENT>
<SENT sid="165" pm="."><plain>The study was comprised of 410 patients with metastatic (75%) or locally advanced (25%) biliary tract cancers. </plain></SENT>
<SENT sid="166" pm="."><plain>Data from the trial demonstrated that the combination of gemcitabine and cisplatin offered a significant progression-free (median of 8.4 versus 6.5 months; hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.57–0.90; P = 0.003) as well as overall survival (median of 11.7 versus 8.3 months; HR: 0.70; 95% CI: 0.54–0.89; P = 0.002) compared with gemcitabine alone at a median follow-up of 8.2 months. </plain></SENT>
<SENT sid="167" pm="."><plain>While this study did not stratify bile duct cancers by location, upon subgroup analysis, the survival benefit persisted when patients with cholangiocarcinoma (59%, 241 patients) were evaluated (HR: 0.54; 95% CI: 0.34–0.94) [85]. </plain></SENT>
<SENT sid="168" pm="."><plain>This “doublet” regimen is now considered standard of care due to the survival advantage noted in this trial, as well as its relatively favorable safety profile. </plain></SENT>
<SENT sid="169" pm="."><plain>The ABC-02 trial also demonstrated the possibility of performing quality phase III trials in rare diseases such as cholangiocarcinoma. </plain></SENT>
<SENT sid="170" pm="."><plain>The use of chemotherapy for ICC in the adjuvant postsurgical setting is even less well studied. </plain></SENT>
<SENT sid="171" pm="."><plain>A small study from China looked at 40 patients receiving adjuvant gemcitabine after resection for biliary tract cancer and showed an overall increase in survival on subgroup analysis for ICC patients (HR: 0.09; 95% CI: 0.01–0.67) [86]. </plain></SENT>
<SENT sid="172" pm="."><plain>This study, however, was very small and the results are somewhat difficult to interpret in isolation. </plain></SENT>
</text></p><p><text><SENT sid="173" pm="."><plain>Given the poor results achieved with cytotoxic chemotherapy, there has been interest in understanding potential targetable molecular mechanisms and mutations critical for oncogenesis in cholangiocarcinoma. </plain></SENT>
<SENT sid="174" pm="."><plain>Targets of the vascular endothelial growth factor (VEGF) pathway, involved in angiogenesis, and epidermal growth factor (EGF) pathway, involved in cell proliferation, have been studied in several phase II trials. </plain></SENT>
<SENT sid="175" pm="."><plain>Agents such as sorafenib [87, 88], erlotinib [89–91], lapatinib [92], panitumumab [93], cetuximab [94], sunitinib [95], and bevacizumab [89, 96] have all been evaluated in phase II trials as single agents or in combination with gemcitabine combination with no significant increase in overall survival noted. </plain></SENT>
<SENT sid="176" pm="."><plain>Ongoing study of these pathways as well as others found to be implicated in cholangiocarcinoma including map kinase pathway, hepatocyte growth factor, BRAF, and platelet derived growth factor hopefully will lead to effective targeted therapy (Figure 3) [97]. </plain></SENT>
</text></p></sec><sec id="sec8.2"><title><text><SENT sid="177" pm="."><plain>8.2. </plain></SENT>
<SENT sid="178" pm="."><plain>Radiation </plain></SENT>
</text></title><p><text><SENT sid="179" pm="."><plain>The role of external beam radiation therapy in the adjuvant setting as well as in inoperable ICC treatment is controversial. </plain></SENT>
<SENT sid="180" pm="."><plain>In the adjuvant setting, most studies do not break down patients by location of cholangiocarcinoma. </plain></SENT>
<SENT sid="181" pm="."><plain>In a retrospective study by Shinohara et al., 3,839 patients with ICC in the SEER database were analyzed. </plain></SENT>
<SENT sid="182" pm="."><plain>7% of the patients analyzed underwent surgical resection and also received adjuvant radiation therapy. </plain></SENT>
<SENT sid="183" pm="."><plain>The median overall survival was higher among patients who underwent surgery plus adjuvant radiation therapy versus surgery alone (11 versus 6 months; P = 0.014) [98]. </plain></SENT>
<SENT sid="184" pm="."><plain>While this study suggested the possible benefit of radiation in patients with R1 resections, it was retrospective, and future prospective trials are needed to validate the benefit of radiation therapy as a local treatment in the adjuvant setting. </plain></SENT>
</text></p><p><text><SENT sid="185" pm="."><plain>The utilization of radiation for ICC has been examined more in the unresectable setting. </plain></SENT>
<SENT sid="186" pm="."><plain>Zeng et al. published a small case-control study of external beam radiotherapy for ICC in which 22 unresectable patients received a median total of 50 Gy of radiation therapy given in 2 Gy/fraction daily doses [99]. </plain></SENT>
<SENT sid="187" pm="."><plain>The 1- and 2-year overall survival among patients with unresectable ICC who underwent radiotherapy versus those patients who did not was 36.1% versus 19% and 5.2% versus 4.7%, respectively; in addition, the objective response rate was 36.4%. </plain></SENT>
<SENT sid="188" pm="."><plain>In a separate phase II study from University of Michigan, 46 patients with unresectable ICC were treated and evaluated [100]. </plain></SENT>
<SENT sid="189" pm="."><plain>Of note, patients with ICC who underwent hyperfactionated radiation therapy with concurrent hepatic arterial fluorodeoxyuridine with a median dose of 60.75 Gy had a significantly improved overall survival compared with historical controls (13.3 months; P &lt; 0.008) [100]. </plain></SENT>
<SENT sid="190" pm="."><plain>The authors reported that tumor dose was strongly associated with survival, as patients who received doses greater than or equal to 75 Gy had a better median survival (23.9 months) compared with patients who received a lower dose (14.9 months; P &lt; 0.01) [100]. </plain></SENT>
<SENT sid="191" pm="."><plain>In yet another study by the Mayo Clinic, the authors reported on 10 patients with unresectable or recurrent ICC treated with abdominal stereotactic body radiotherapy (SBRT) [101]. </plain></SENT>
<SENT sid="192" pm="."><plain>Patients were treated with a median of 55 Gy and had a median follow-up of 14 months. </plain></SENT>
<SENT sid="193" pm="."><plain>Local control, defined as freedom from progression in the SBRT field, was 100%; however, 4 patients experienced progression at other sites. </plain></SENT>
<SENT sid="194" pm="."><plain>Overall survival estimates at 6 and 12 months were 83% and 73%, respectively [101]. </plain></SENT>
</text></p><p><text><SENT sid="195" pm="."><plain>Yttrium-90 radioembolization both alone and in combination with chemotherapy has been studied as an alternative treatment option in patients with unresectable ICC. </plain></SENT>
<SENT sid="196" pm="."><plain>A pooled analysis of 11 previously published studies showed an overall weighted median survival of 15.5 months (range 7–22.2) from the initiation of treatment [102]. </plain></SENT>
<SENT sid="197" pm="."><plain>While none of these were randomized trials, the outcomes compare well with published overall survival after treatment with systemic cisplatin-gemcitabine (11.7 months) [85] and TACE (13.8 months) [103]. </plain></SENT>
<SENT sid="198" pm="."><plain>These studies provide promising evidence of success of radiation therapy as a local, noninvasive treatment option in ICC; however, further validation is needed in an upcoming prospective multicenter trial. </plain></SENT>
</text></p></sec><sec id="sec8.3"><title><text><SENT sid="199" pm="."><plain>8.3. </plain></SENT>
<SENT sid="200" pm="."><plain>Intra-Arterial Therapy </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>Another local treatment option for unresectable ICC is intra-arterial therapy, which most commonly involves transarterial chemoembolization (TACE). </plain></SENT>
<SENT sid="202" pm="."><plain>TACE was first described in the early 1980s in the treatment of HCC [104–106] and has more recently been demonstrated to provide survival benefit for patients with HCC compared with best supportive care [107, 108]. </plain></SENT>
<SENT sid="203" pm="."><plain>Data on intra-arterial therapy for ICC are limited. </plain></SENT>
<SENT sid="204" pm="."><plain>A 2005 study of 17 patients with unresectable ICC at Johns Hopkins Hospital from 1995 to 2004 found that the treatment was well tolerated by 82% of the patients [109]. </plain></SENT>
<SENT sid="205" pm="."><plain>Imaging was performed 4–6 weeks following each TACE treatment to determine clinical response and the need for additional treatments. </plain></SENT>
<SENT sid="206" pm="."><plain>The median overall survival in this study was 23 months and two patients were converted to resectable disease and ultimately underwent an R0 resection [109]. </plain></SENT>
<SENT sid="207" pm="."><plain>A 2008 University of Pittsburg study examined the use of TACE in 48 patients (37 with central cholangiocarcinoma and 5 with peripheral tumors) with unresectable cholangiocarcinoma. </plain></SENT>
<SENT sid="208" pm="."><plain>This study found that TACE with a median of 3.5 treatments using a gemcitabine-cisplatin combination resulted in an increased overall survival compared with gemcitabine alone TACE treatment (13.8 versus 6.3 months) [110]. </plain></SENT>
<SENT sid="209" pm="."><plain>A separate 2013 retrospective study investigated 198 patients with advanced ICC from five major hepatobiliary centers in the US who were treated with intra-arterial therapy between 1992 and 2012 [103]. </plain></SENT>
<SENT sid="210" pm="."><plain>A majority of the patients underwent TACE and, on assessment of tumor response, 25.5% of the patients were noted to have a complete or partial response [103]. </plain></SENT>
<SENT sid="211" pm="."><plain>When evaluated with modified response evaluation criteria in solid tumors (mRECIST), intra-arterial therapy was independently associated with improved survival [103]. </plain></SENT>
<SENT sid="212" pm="."><plain>These studies suggest that intra-arterial therapies, such as TACE, may provide a therapeutic benefit to some patients and should be considered when treating patients with advanced disease. </plain></SENT>
</text></p></sec><sec id="sec8.4"><title><text><SENT sid="213" pm="."><plain>8.4. </plain></SENT>
<SENT sid="214" pm="."><plain>Ablation </plain></SENT>
</text></title><p><text><SENT sid="215" pm="."><plain>For patients with small lesions, who are otherwise unable to undergo resection, radiofrequency (RFA) or microwave ablation is another treatment option. </plain></SENT>
<SENT sid="216" pm="."><plain>While ablation is a standard treatment for HCC, there have only been few small studies regarding its efficacy in ICC [3, 111–117]. </plain></SENT>
<SENT sid="217" pm="."><plain>Ablation may be effective in providing local control of small (&lt;3–5 cm) lesions; however the data are scarce. </plain></SENT>
<SENT sid="218" pm="."><plain>In the few reported studies to date, most with patient sample sizes of 6–17 patients, primary technical effectiveness measured by early necrosis was seen in 90–100% of small tumors (&lt;3.5 cm). </plain></SENT>
<SENT sid="219" pm="."><plain>One- and 3-year survival ranged from 84.6% to 100% and 43.3% to 83.3%, respectively. </plain></SENT>
<SENT sid="220" pm="."><plain>Median overall survival ranged from 33 to 38.5 months, suggesting that ablation may have a survival benefit [3, 111–117]. </plain></SENT>
</text></p></sec><sec id="sec8.5"><title><text><SENT sid="221" pm="."><plain>8.5. </plain></SENT>
<SENT sid="222" pm="."><plain>Liver Transplantation </plain></SENT>
</text></title><p><text><SENT sid="223" pm="."><plain>Liver transplantation as a treatment for ICC remains controversial. </plain></SENT>
<SENT sid="224" pm="."><plain>The role of transplantation in perihilar cholangiocarcinoma is significantly more defined; for perihilar cholangiocarcinoma, there are strict selection criteria, including the requirement of neoadjuvant chemotherapy, with good long-term outcomes such as a recurrence-free survival at 5 years of 65% [118]. </plain></SENT>
<SENT sid="225" pm="."><plain>The data on transplantation for ICC, however, are not as defined. </plain></SENT>
<SENT sid="226" pm="."><plain>UCLA reported on 38 patients who underwent liver transplant for intrahepatic or hilar cholangiocarcinoma. </plain></SENT>
<SENT sid="227" pm="."><plain>The 5-year tumor recurrence-free survival was higher in the transplant group compared with those who underwent hepatectomy (33% versus 0%; P = 0.05). </plain></SENT>
<SENT sid="228" pm="."><plain>In the transplant group, neoadjuvant and adjuvant therapies resulted in better patient survival compared with no therapy or adjuvant therapy only (47% versus 20% versus 33%, resp.; P = 0.03) [119]. </plain></SENT>
<SENT sid="229" pm="."><plain>However, this study did not separate out intrahepatic from hilar lesions, making the findings difficult to interpret. </plain></SENT>
<SENT sid="230" pm="."><plain>A retrospective study from China evaluated 20 patients with ICC who underwent liver transplantation and reported actuarial survival at 1, 2, 3, and 5 years of 84.2%, 43.7%, 32.7%, and 21.8%, respectively [120]. </plain></SENT>
<SENT sid="231" pm="."><plain>Tumor-free survival at 1, 2, 3, and 5 years was 55.6%, 43.2%, 28.8%, and 18.8%, respectively. </plain></SENT>
<SENT sid="232" pm="."><plain>On multivariate analysis, lymph node invasion, macrovascular invasion, and multiple tumors were independent predictors of survival [120]. </plain></SENT>
<SENT sid="233" pm="."><plain>A retrospective multicenter study from Spain reported on 29 patients with cirrhosis and ICC &lt;2 cm on histologic sectioning after liver transplantation [121]. </plain></SENT>
<SENT sid="234" pm="."><plain>Patients with small tumors had an actuarial survival at 1, 3, and 5 years of 100%, 73%, and 73%, respectively [121]. </plain></SENT>
<SENT sid="235" pm="."><plain>There were no recurrences in patients with tumors &lt;2 cm compared with a recurrence of 36.4% among patients with &gt;2 cm ICC [121]. </plain></SENT>
<SENT sid="236" pm="."><plain>While liver transplantation for ICC may have a future role, the overall survival outcomes at the current time remain generally poor. </plain></SENT>
<SENT sid="237" pm="."><plain>As such, transplantation for ICC should probably only be done in a strict protocol-based setting. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="sec9"><title><text><SENT sid="238" pm="."><plain>9. </plain></SENT>
<SENT sid="239" pm="."><plain>Summary </plain></SENT>
</text></title><p><text><SENT sid="240" pm="."><plain>ICC is the second most common primary hepatic malignancy and is increasing in incidence in the United States. </plain></SENT>
<SENT sid="241" pm="."><plain>The disease remains poorly understood; however patients who are eligible should undergo surgical resection, as an R0 resection remains the only potentially curative treatment. </plain></SENT>
<SENT sid="242" pm="."><plain>Resection often requires a technically complex surgery that often involves an extended hepatic resection and therefore these patients are probably best served at a high volume center. </plain></SENT>
<SENT sid="243" pm="."><plain>Unfortunately, a large number of patients with ICC will present with unresectable disease. </plain></SENT>
<SENT sid="244" pm="."><plain>Therapeutic options for patients with advanced disease include systemic and locoregional options. </plain></SENT>
<SENT sid="245" pm="."><plain>Ultimately, ICC remains a complex clinical challenge that demands a multidisciplinary approach. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="246" pm="."><plain>Dr. Geschwind has unrelated grant support from Abdulmalik Research Fund, Alice Pratt Liver Cancer Fund, Bayer Healthcare, BTG (Biocompatibles/Nordion), Boston Scientific Corporation, DOD, Genentech, Guerbet, NCI RO1, Philips Health Care, RSNA, SIR, and Threshold Pharmaceuticals. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec><title>Disclosure</title><p>Dr. Geschwind is a consultant for Bayer Healthcare, BTG (Biocompatibles/Nordion), Boston Scientific Corporation, Guerbet, Koo Foundation, Onyx Pharmaceuticals, Philips Medical System, PreScience Labs, and Threshold Pharmaceuticals.</p></sec></SecTag><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>Dr. Pawlik and Dr. Lafaro report no conflict of interests.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="247" pm="."><plain>1FanB.MalatoY.CalvisiD. </plain></SENT>
<SENT sid="248" pm="."><plain>F.Cholangiocarcinomas can originate from hepatocytes in miceThe Journal of Clinical Investigation201212282911291510.1172/jci632122-s2.0-8486477312622797301 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="249" pm="."><plain>2SekiyaS.SuzukiA.Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytesThe Journal of Clinical Investigation2012122113914391810.1172/jci630652-s2.0-8486862555223023701 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="250" pm="."><plain>3BridgewaterJ.GalleP. </plain></SENT>
<SENT sid="251" pm="."><plain>R.KhanS. </plain></SENT>
<SENT sid="252" pm="."><plain>A.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinomaJournal of Hepatology20146061268128910.1016/j.jhep.2014.01.0212-s2.0-8490099272724681130 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="253" pm="."><plain>4BragazziM. </plain></SENT>
<SENT sid="254" pm="."><plain>C.CardinaleV.CarpinoG.Cholangiocarcinoma: epidemiology and risk factorsTranslational Gastrointestinal Cancer201212132 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="255" pm="."><plain>5PoultsidesG. </plain></SENT>
<SENT sid="256" pm="."><plain>A.ZhuA. </plain></SENT>
<SENT sid="257" pm="."><plain>X.ChotiM. </plain></SENT>
<SENT sid="258" pm="."><plain>A.PawlikT. </plain></SENT>
<SENT sid="259" pm="."><plain>M.Intrahepatic cholangiocarcinomaSurgical Clinics of North America201090481783710.1016/j.suc.2010.04.0112-s2.0-7795464134820637950 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="260" pm="."><plain>6ShaibY. </plain></SENT>
<SENT sid="261" pm="."><plain>H.DavilaJ. </plain></SENT>
<SENT sid="262" pm="."><plain>A.McGlynnK.El-SeragH. </plain></SENT>
<SENT sid="263" pm="."><plain>B.Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?Journal of Hepatology200440347247710.1016/j.jhep.2003.11.0302-s2.0-124231480215123362 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="264" pm="."><plain>7Taylor-RobinsonS. </plain></SENT>
<SENT sid="265" pm="."><plain>D.FosterG. </plain></SENT>
<SENT sid="266" pm="."><plain>R.AroraS.HargreavesS.ThomasH. </plain></SENT>
<SENT sid="267" pm="."><plain>C.Increase in primary liver cancer in the UK, 1979–94The Lancet19973509085114211432-s2.0-0030699243 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="268" pm="."><plain>8KatoI.KuroishiT.TominagaS.Descriptive epidemiology of subsites of cancers of the liver, biliary tract and pancreas in JapanJapanese Journal of Clinical Oncology19902032322372-s2.0-00254906422255100 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="269" pm="."><plain>9WelzelT. </plain></SENT>
<SENT sid="270" pm="."><plain>M.McGlynnK. </plain></SENT>
<SENT sid="271" pm="."><plain>A.HsingA. </plain></SENT>
<SENT sid="272" pm="."><plain>W.O'BrienT. </plain></SENT>
<SENT sid="273" pm="."><plain>R.PfeifferR. </plain></SENT>
<SENT sid="274" pm="."><plain>M.Impact of classification of hilar cholangiocarcinomas (Klatskin Tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United StatesJournal of the National Cancer Institute2006981287387510.1093/jnci/djj2342-s2.0-3374527587716788161 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="275" pm="."><plain>10PatelT.Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United StatesHepatology20013361353135710.1053/jhep.2001.250872-s2.0-003498253611391522 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="276" pm="."><plain>11Taylor-RobinsonS. </plain></SENT>
<SENT sid="277" pm="."><plain>D.ToledanoM. </plain></SENT>
<SENT sid="278" pm="."><plain>B.AroraS.Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998Gut200148681682010.1136/gut.48.6.8162-s2.0-003500059711358902 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="279" pm="."><plain>12von HahnT.CiesekS.WegenerG.Epidemiological trends in incidence and mortality of hepatobiliary cancers in GermanyScandinavian Journal of Gastroenterology20114691092109810.3109/00365521.2011.5894722-s2.0-8005171695521692710 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="280" pm="."><plain>13AlvaroD.CrocettiE.FerrettiS.BragazziM. </plain></SENT>
<SENT sid="281" pm="."><plain>C.CapocacciaR.Descriptive epidemiology of cholangiocarcinoma in ItalyDigestive and Liver Disease201042749049510.1016/j.dld.2009.10.0092-s2.0-7795555058520022823 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="282" pm="."><plain>14WelzelT. </plain></SENT>
<SENT sid="283" pm="."><plain>M.GraubardB. </plain></SENT>
<SENT sid="284" pm="."><plain>I.El-SeragH. </plain></SENT>
<SENT sid="285" pm="."><plain>B.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population—based case—control studyClinical Gastroenterology and Hepatology200751221122817689296 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="286" pm="."><plain>15PalmerW. </plain></SENT>
<SENT sid="287" pm="?"><plain>C.PatelT.Are common factors involved in the pathogenesis of primary liver cancers? </plain></SENT>
<SENT sid="288" pm="."><plain>A meta-analysis of risk factors for intrahepatic cholangiocarcinomaJournal of Hepatology2012571697610.1016/j.jhep.2012.02.0222-s2.0-8486266091222420979 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="289" pm="."><plain>16ShaibY. </plain></SENT>
<SENT sid="290" pm="."><plain>H.El-SeragH. </plain></SENT>
<SENT sid="291" pm="."><plain>B.DavilaJ. </plain></SENT>
<SENT sid="292" pm="."><plain>A.MorganR.McglynnK. </plain></SENT>
<SENT sid="293" pm="."><plain>A.Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control studyGastroenterology2005128362062610.1053/j.gastro.2004.12.0482-s2.0-1574438943415765398 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="294" pm="."><plain>17ZhouH.-B.HuJ.-Y.HuH.-P.Hepatitis B virus infection and intrahepatic cholangiocarcinomaWorld Journal of Gastroenterology201420195721572910.3748/wjg.v20.i19.57212-s2.0-8490119700724914333 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="295" pm="."><plain>18MatsumotoK.OnoyamaT.KawataS.Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinomaInternal Medicine201453765165410.2169/internalmedicine.53.14102-s2.0-8489744554624694471 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="296" pm="."><plain>19LeeT. </plain></SENT>
<SENT sid="297" pm="."><plain>Y.LeeS. </plain></SENT>
<SENT sid="298" pm="."><plain>S.JungS. </plain></SENT>
<SENT sid="299" pm="."><plain>W.Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control studyThe American Journal of Gastroenterology200810371716172010.1111/j.1572-0241.2008.01796.x2-s2.0-5064911282018557716 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="300" pm="."><plain>20SørensenH. </plain></SENT>
<SENT sid="301" pm="."><plain>T.FriisS.OlsenJ. </plain></SENT>
<SENT sid="302" pm="."><plain>H.Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in DenmarkHepatology199828492192510.1002/hep.5102804042-s2.0-00316812469755226 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="303" pm="."><plain>21WelzelT. </plain></SENT>
<SENT sid="304" pm="."><plain>M.MellemkjaerL.GloriaG.Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control studyInternational Journal of Cancer2007120363864110.1002/ijc.222832-s2.0-3384579285917109384 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="305" pm="."><plain>22YamamotoS.KuboS.HaiS.Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinomaCancer Science200495759259510.1111/j.1349-7006.2004.tb02492.x2-s2.0-414313123515245596 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="306" pm="."><plain>23El-SeragH. </plain></SENT>
<SENT sid="307" pm="."><plain>B.EngelsE. </plain></SENT>
<SENT sid="308" pm="."><plain>A.LandgrenO.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veteransHepatology200949111612310.1002/hep.226062-s2.0-5894909567819085911 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="309" pm="."><plain>24DonatoF.GelattiU.TaggerA.Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in ItalyCancer Causes &amp; Control2001121095996410.1023/a:10137472285722-s2.0-003568309211808716 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="310" pm="."><plain>25KobayashiM.IkedaK.SaitohS.Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with Hepatitis C virus-related cirrhosisCancer200088112471247710.1002/1097-0142(20000601)88:11&amp;lt;2471::AID-CNCR7&gt;3.0.CO;2-T2-s2.0-003421234710861422 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="311" pm="."><plain>26HashimotoE.TokushigeK.Prevalence, gender, ethnic variations, and prognosis of NASHJournal of Gastroenterology201146supplement 1636910.1007/s00535-010-0311-82-s2.0-7865135206720844903 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="312" pm="."><plain>27GraingeM. </plain></SENT>
<SENT sid="313" pm="."><plain>J.WestJ.Solaymani-DodaranM.AithalG. </plain></SENT>
<SENT sid="314" pm="."><plain>P.CardT. </plain></SENT>
<SENT sid="315" pm="."><plain>R.The antecedents of biliary cancer: a primary care case-control study in the United KingdomBritish Journal of Cancer2009100117818010.1038/sj.bjc.66047652-s2.0-5814925041119018260 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="316" pm="."><plain>28ReddyS. </plain></SENT>
<SENT sid="317" pm="."><plain>K.HyderO.MarshJ. </plain></SENT>
<SENT sid="318" pm="."><plain>W.Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinomaJournal of Gastrointestinal Surgery20131774875523355033 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="319" pm="."><plain>29SempouxC.JibaraG.WardS. </plain></SENT>
<SENT sid="320" pm="."><plain>C.Intrahepatic cholangiocarcinoma: new insights in pathologySeminars in Liver Disease2011311496010.1055/s-0031-12728392-s2.0-7995190234121344350 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="321" pm="."><plain>30El-ChaficA. </plain></SENT>
<SENT sid="322" pm="."><plain>H.DewittJ.LeBlancJ. </plain></SENT>
<SENT sid="323" pm="."><plain>K.Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patientsEndoscopy2013451188388910.1055/s-0033-13447602-s2.0-8488699758824165813 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="324" pm="."><plain>31NakajimaT.KondoY.MiyazakiM.OkuiK.A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreadingHuman Pathology198819101228123410.1016/s0046-8177(88)80156-42-s2.0-00237985452844646 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="325" pm="."><plain>32NakanumaY.HaradaK.IshikawaA.ZenY.SasakiM.Anatomic and molecular pathology of intrahepatic cholangiocarcinomaJournal of Hepato-Biliary-Pancreatic Surgery200310426528110.1007/s00534-002-0729-32-s2.0-024243884214598145 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="326" pm="."><plain>33NakanumaY.SasakiM.IkedaH.Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesisHepatology Research200838432533410.1111/j.1872-034X.2007.00312.x2-s2.0-4004908990918093122 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="327" pm="."><plain>34NakanumaY.SatoY.HaradaK.SasakiM.XuJ.IkedaH.Pathological classification of intrahepatic cholangiocarcinoma based on a new conceptWorld Journal of Hepatology201021241942710.4254/wjh.v2.i12.4192-s2.0-7996000161521191517 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="328" pm="."><plain>35NakanumaY.XuJ.HaradaK.Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseasesPathology International201161529830510.1111/j.1440-1827.2011.02665.x2-s2.0-7995499648821501296 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="329" pm="."><plain>36GoodmanZ. </plain></SENT>
<SENT sid="330" pm="."><plain>D.Neoplasms of the liverModern Pathology2007201S49S6010.1038/modpathol.38006822-s2.0-3424832785617486052 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="331" pm="."><plain>37PatelA. </plain></SENT>
<SENT sid="332" pm="."><plain>H.HarnoisD. </plain></SENT>
<SENT sid="333" pm="."><plain>M.KleeG. </plain></SENT>
<SENT sid="334" pm="."><plain>G.LarussoN. </plain></SENT>
<SENT sid="335" pm="."><plain>F.GoresG. </plain></SENT>
<SENT sid="336" pm="."><plain>J.The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitisThe American Journal of Gastroenterology200095120420710.1016/s0002-9270(99)00744-32-s2.0-003398605010638584 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="337" pm="."><plain>38TamandlD.HerbergerB.GruenbergerB.PuhallaH.KlingerM.GruenbergerT.Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinomaAnnals of Surgical Oncology200815102787279410.1245/s10434-008-0081-12-s2.0-5164909868218685896 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="338" pm="."><plain>39NishinoR.HondaM.YamashitaT.Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinomaJournal of Hepatology200849220721610.1016/j.jhep.2008.03.0252-s2.0-4624910980918490072 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="339" pm="."><plain>40UenishiT.YamazakiO.TanakaH.Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinomaAnnals of Surgical Oncology200815258358910.1245/s10434-007-9650-y2-s2.0-4064908436117955299 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="340" pm="."><plain>41MillerG.SchwartzL. </plain></SENT>
<SENT sid="341" pm="."><plain>H.D'AngelicaM.The use of imaging in the diagnosis and staging of hepatobiliary malignanciesSurgical Oncology Clinics of North America200716234336810.1016/j.soc.2007.04.0012-s2.0-3424987459417560517 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="342" pm="."><plain>42GoreR. </plain></SENT>
<SENT sid="343" pm="."><plain>M.ShelhamerR. </plain></SENT>
<SENT sid="344" pm="."><plain>P.Biliary tract neoplasms: diagnosis and stagingCancer Imaging20077S15S2310.1102/1470-7330.2007.90162-s2.0-3584893390717921093 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="345" pm="."><plain>43VallsC.GumàA.PuigI.Intrahepatic peripheral cholangiocarcinoma: CT evaluationAbdominal Imaging200025549049610.1007/s0026100000792-s2.0-003384231610931983 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="346" pm="."><plain>44IavaroneM.PiscagliaF.VavassoriS.Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosisJournal of Hepatology20135861188119310.1016/j.jhep.2013.02.0132-s2.0-8487792143223485522 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="347" pm="."><plain>45LacomisJ. </plain></SENT>
<SENT sid="348" pm="."><plain>M.BaronR. </plain></SENT>
<SENT sid="349" pm="."><plain>L.OliverJ. </plain></SENT>
<SENT sid="350" pm="."><plain>H.IIINalesnikM. </plain></SENT>
<SENT sid="351" pm="."><plain>A.FederleM. </plain></SENT>
<SENT sid="352" pm="."><plain>P.Cholangiocarcinoma: delayed CT contrast enhancement patternsRadiology199720319810410.1148/radiology.203.1.91224232-s2.0-00309005959122423 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="353" pm="."><plain>46ChongY. </plain></SENT>
<SENT sid="354" pm="."><plain>S.KimY. </plain></SENT>
<SENT sid="355" pm="."><plain>K.LeeM. </plain></SENT>
<SENT sid="356" pm="."><plain>W.Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRIClinical Radiology201267876677310.1016/j.crad.2012.01.0042-s2.0-8486319680622425613 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="357" pm="."><plain>47EdgeS. </plain></SENT>
<SENT sid="358" pm="."><plain>B.ComptonC. </plain></SENT>
<SENT sid="359" pm="."><plain>C.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnnals of Surgical Oncology20101761471147410.1245/s10434-010-0985-42-s2.0-7795481805820180029 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="360" pm="."><plain>48OkabayashiT.YamamotoJ.KosugeT.A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variablesCancer2001929237423832-s2.0-003549861011745293 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="361" pm="."><plain>49YamasakiS.Intrahepatic cholangiocarcinoma: macroscopic type and stage classificationJournal of Hepato-Biliary-Pancreatic Surgery200310428829110.1007/s00534-002-0732-82-s2.0-024252235614598147 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="362" pm="."><plain>50NathanH.AloiaT. </plain></SENT>
<SENT sid="363" pm="."><plain>A.VautheyJ.-N.A proposed staging system for intrahepatic cholangiocarcinomaAnnals of Surgical Oncology2009161142210.1245/s10434-008-0180-z2-s2.0-5854911445618987916 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="364" pm="."><plain>51FargesO.FuksD.Le TreutY.-P.AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study groupCancer2011117102170217710.1002/cncr.257122-s2.0-7995550306621523730 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="365" pm="."><plain>52GoereD.WagholikarG. </plain></SENT>
<SENT sid="366" pm="."><plain>D.PessauxP.Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinomaSurgical Endoscopy and Other Interventional Techniques200620572172510.1007/s00464-005-0583-x2-s2.0-3374555422116508808 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="367" pm="."><plain>53WeberS. </plain></SENT>
<SENT sid="368" pm="."><plain>M.JarnaginW. </plain></SENT>
<SENT sid="369" pm="."><plain>R.KlimstraD.DeMatteoR. </plain></SENT>
<SENT sid="370" pm="."><plain>P.FongY.BlumgartL. </plain></SENT>
<SENT sid="371" pm="."><plain>H.Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomesJournal of the American College of Surgeons2001193438439110.1016/s1072-7515(01)01016-x2-s2.0-003482823711584966 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="372" pm="."><plain>54TanJ. </plain></SENT>
<SENT sid="373" pm="."><plain>C. </plain></SENT>
<SENT sid="374" pm="."><plain>C.CoburnN. </plain></SENT>
<SENT sid="375" pm="."><plain>G.BaxterN. </plain></SENT>
<SENT sid="376" pm="."><plain>N.KissA.LawC. </plain></SENT>
<SENT sid="377" pm="."><plain>H. </plain></SENT>
<SENT sid="378" pm="."><plain>L.Surgical management of intrahepatic cholangiocarcinoma—a population-based studyAnnals of Surgical Oncology200815260060810.1245/s10434-007-9627-x2-s2.0-4064911212817987347 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="379" pm="."><plain>55SotiropoulosG. </plain></SENT>
<SENT sid="380" pm="."><plain>C.BockhornM.SgourakisG.R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysisDigestive Diseases and Sciences200954488789410.1007/s10620-008-0408-62-s2.0-6324912009918712480 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="381" pm="."><plain>56EndoI.GonenM.YoppA. </plain></SENT>
<SENT sid="382" pm="."><plain>C.Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionAnnals of Surgery20082481849610.1097/sla.0b013e318176c4d32-s2.0-4894911894418580211 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="383" pm="."><plain>57NakagawaT.KamiyamaT.KurauchiN.Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinomaWorld Journal of Surgery200529672873310.1007/s00268-005-7761-92-s2.0-2394446179615880276 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="384" pm="."><plain>58MavrosM. </plain></SENT>
<SENT sid="385" pm="."><plain>N.EconomopoulosK. </plain></SENT>
<SENT sid="386" pm="."><plain>P.AlexiouV. </plain></SENT>
<SENT sid="387" pm="."><plain>G.PawlikT. </plain></SENT>
<SENT sid="388" pm="."><plain>M.Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysisJAMA Surgery201410.1001/jamasurg.2013.5137 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="389" pm="."><plain>59LiD.-Y.ZhangH.-B.YangN.QuanY.YangG.-S.Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric seriesWorld Journal of Gastroenterology201319479084909110.3748/wjg.v19.i47.90842-s2.0-8489089481524379635 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="390" pm="."><plain>60de JongM. </plain></SENT>
<SENT sid="391" pm="."><plain>C.NathanH.SotiropoulosG. </plain></SENT>
<SENT sid="392" pm="."><plain>C.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessmentJournal of Clinical Oncology201129233140314510.1200/jco.2011.35.65192-s2.0-8005173461121730269 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="393" pm="."><plain>61BektasH.YeyrekC.KleineM.Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experienceJournal of Hepato-Biliary-Pancreatic Sciences201522213113710.1002/jhbp.15825159731 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="394" pm="."><plain>62NathanH.PawlikT. </plain></SENT>
<SENT sid="395" pm="."><plain>M.WolfgangC. </plain></SENT>
<SENT sid="396" pm="."><plain>L.ChotiM. </plain></SENT>
<SENT sid="397" pm="."><plain>A.CameronJ. </plain></SENT>
<SENT sid="398" pm="."><plain>L.SchulickR. </plain></SENT>
<SENT sid="399" pm="."><plain>D.Trends in survival after surgery for cholangiocarcinoma: a 30-Year population-based SEER database analysisJournal of Gastrointestinal Surgery200711111488149610.1007/s11605-007-0282-02-s2.0-3514886628717805937 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="400" pm="."><plain>63KonstadoulakisM. </plain></SENT>
<SENT sid="401" pm="."><plain>M.RoayaieS.GomatosI. </plain></SENT>
<SENT sid="402" pm="."><plain>P.Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcomeSurgery2008143336637410.1016/j.surg.2007.10.0102-s2.0-3914911378318291258 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="403" pm="."><plain>64LangH.SotiropoulosG. </plain></SENT>
<SENT sid="404" pm="."><plain>C.SgourakisG.Operations for intrahepatic cholangiocarcinoma: single—institution experience of 158 patientsJournal of the American College of Surgeons2009208221822810.1016/j.jamcollsurg.2008.10.0172-s2.0-5824909920319228533 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="405" pm="."><plain>65NakagohriT.KinoshitaT.KonishiM.TakahashiS.GotohdaN.Surgical outcome and prognostic factors in intrahepatic cholangiocarcinomaWorld Journal of Surgery200832122675268010.1007/s00268-008-9778-32-s2.0-5634910778418843437 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="406" pm="."><plain>66ShimadaK.SanoT.NaraS.Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvementSurgery2009145441141610.1016/j.surg.2008.11.0102-s2.0-6234910122919303990 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="407" pm="."><plain>67ChoiS.-B.KimK.-S.ChoiJ.-Y.The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survivalAnnals of Surgical Oncology200916113028305610.1245/s10434-009-0624-02-s2.0-7035042324219626373 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="408" pm="."><plain>68InoueK.MakuuchiM.TakayamaT.Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinomaSurgery2000127549850510.1067/msy.2000.1046732-s2.0-003411284410819057 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="409" pm="."><plain>69OhtsukaM.ItoH.KimuraF.Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survivalThe British Journal of Surgery200289121525153110.1046/j.1365-2168.2002.02268.x2-s2.0-003644473012445060 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="410" pm="."><plain>70PaikK. </plain></SENT>
<SENT sid="411" pm="."><plain>Y.JungJ. </plain></SENT>
<SENT sid="412" pm="."><plain>C.HeoJ. </plain></SENT>
<SENT sid="413" pm="."><plain>S.ChoiS. </plain></SENT>
<SENT sid="414" pm="."><plain>H.ChoiD. </plain></SENT>
<SENT sid="415" pm="."><plain>W.KimY. </plain></SENT>
<SENT sid="416" pm="."><plain>I.What prognostic factors are important for resected intrahepatic cholangiocarcinoma?Journal of Gastroenterology and Hepatology200823576677010.1111/j.1440-1746.2007.05040.x2-s2.0-4204908746817868336 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="417" pm="."><plain>71UenishiT.KuboS.YamazakiO.Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastasesJournal of Hepato-Biliary-Pancreatic Surgery200815441742210.1007/s00534-007-1315-52-s2.0-4874909419818670844 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="418" pm="."><plain>72DeOliveiraM. </plain></SENT>
<SENT sid="419" pm="."><plain>L.CunninghamS. </plain></SENT>
<SENT sid="420" pm="."><plain>C.CameronJ. </plain></SENT>
<SENT sid="421" pm="."><plain>L.Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institutionAnnals of Surgery2007245575576210.1097/01.sla.0000251366.62632.d32-s2.0-3424763800217457168 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="422" pm="."><plain>73JanY.-Y.YehC.-N.YehT.-S.HwangT.-L.ChenM.-F.Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinomaWorld Journal of Surgery200529789489810.1007/s00268-005-7763-72-s2.0-2774452880515951931 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="423" pm="."><plain>74WeimannA.VarnholtH.SchlittH. </plain></SENT>
<SENT sid="424" pm="."><plain>J.Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinomaBritish Journal of Surgery20008791182118710.1046/j.1365-2168.2000.01532.x2-s2.0-003383198710971425 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="425" pm="."><plain>75HyderO.HatzarasI.SotiropoulosG. </plain></SENT>
<SENT sid="426" pm="."><plain>C.Recurrence after operative management of intrahepatic cholangiocarcinomaSurgery2013153681181810.1016/j.surg.2012.12.0052-s2.0-8487801127323499016 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="427" pm="."><plain>76HyderO.MarquesH.PulitanoC.A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experienceJAMA Surgery2014149543243810.1001/jamasurg.2013.51682-s2.0-8490130792924599477 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="428" pm="."><plain>77ChouF.-F.Sheen-ChenS.-M.ChenY.-S.ChenM.-C.ChenC.-L.Surgical treatment of cholangiocarcinomaHepato-Gastroenterology199744157607652-s2.0-00309502749222685 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="429" pm="."><plain>78AljiffryM.AbdulelahA.WalshM.PeltekianK.AlwaynI.MolinariM.Evidence-based approach to cholangiocarcinoma: a systematic review of the current literatureJournal of the American College of Surgeons2009208113414710.1016/j.jamcollsurg.2008.09.0072-s2.0-5774917076819228515 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="430" pm="."><plain>79GlimeliusB.HoffmanK.SjödénP.-O.Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology19967659360010.1093/oxfordjournals.annonc.a0106762-s2.0-00298165908879373 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="431" pm="."><plain>80EckelF.SchmidR. </plain></SENT>
<SENT sid="432" pm="."><plain>M.Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer200796689690210.1038/sj.bjc.66036482-s2.0-3394738707717325704 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="433" pm="."><plain>81HezelA. </plain></SENT>
<SENT sid="434" pm="."><plain>F.ZhuA. </plain></SENT>
<SENT sid="435" pm="."><plain>X.Systemic therapy for biliary tract cancersThe Oncologist200813441542310.1634/theoncologist.2007-02522-s2.0-4354911660518448556 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="436" pm="."><plain>82Huitzil-MelendezF. </plain></SENT>
<SENT sid="437" pm="."><plain>D.O'ReillyE. </plain></SENT>
<SENT sid="438" pm="."><plain>M.DuffyA.Abou-AlfaG. </plain></SENT>
<SENT sid="439" pm="."><plain>K.Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancersSurgical Oncology Clinics of North America200918236137910.1016/j.soc.2008.12.0062-s2.0-6254910202419306817 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="440" pm="."><plain>83VerderameF.RussoA.Di LeoR.Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancersAnnals of Oncology2006177vii68vii7210.1093/annonc/mdl9552-s2.0-3374561463816760298 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="441" pm="."><plain>84WooS. </plain></SENT>
<SENT sid="442" pm="."><plain>M.LeeW. </plain></SENT>
<SENT sid="443" pm="."><plain>J.KimJ. </plain></SENT>
<SENT sid="444" pm="."><plain>H.Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort studyChemotherapy201459323223810.1159/0003545392-s2.0-8489046565124356333 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="445" pm="."><plain>85ValleJ.WasanH.PalmerD. </plain></SENT>
<SENT sid="446" pm="."><plain>H.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerThe New England Journal of Medicine2010362141273128110.1056/nejmoa09087212-s2.0-7795082282720375404 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="447" pm="."><plain>86YamanakaK.HatanoE.KanaiM.A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancerInternational Journal of Clinical Oncology201419348548910.1007/s10147-013-0578-x2-s2.0-8487879416923765238 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="448" pm="."><plain>87BengalaC.BertoliniF.MalavasiN.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer20101021687210.1038/sj.bjc.66054582-s2.0-7424909881819935794 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="449" pm="."><plain>88El-KhoueiryA. </plain></SENT>
<SENT sid="450" pm="."><plain>B.RankinC. </plain></SENT>
<SENT sid="451" pm="."><plain>J.Ben-JosefE.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaInvestigational New Drugs20123041646165110.1007/s10637-011-9719-02-s2.0-8486672953421748296 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="452" pm="."><plain>89LubnerS. </plain></SENT>
<SENT sid="453" pm="."><plain>J.MahoneyM. </plain></SENT>
<SENT sid="454" pm="."><plain>R.KolesarJ. </plain></SENT>
<SENT sid="455" pm="."><plain>L.Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium studyJournal of Clinical Oncology201028213491349710.1200/jco.2010.28.40752-s2.0-7795529329820530271 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="456" pm="."><plain>90PhilipP. </plain></SENT>
<SENT sid="457" pm="."><plain>A.MahoneyM. </plain></SENT>
<SENT sid="458" pm="."><plain>R.AllmerC.Phase II study of erlotinib in patients with advanced biliary cancerJournal of Clinical Oncology200624193069307410.1200/JCO.2005.05.35792-s2.0-3374597075216809731 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="459" pm="."><plain>91LeeJ.ParkS. </plain></SENT>
<SENT sid="460" pm="."><plain>H.ChangH.-M.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology201213218118810.1016/s1470-2045(11)70301-12-s2.0-8485647638722192731 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="461" pm="."><plain>92RamanathanR. </plain></SENT>
<SENT sid="462" pm="."><plain>K.BelaniC. </plain></SENT>
<SENT sid="463" pm="."><plain>P.SinghD. </plain></SENT>
<SENT sid="464" pm="."><plain>A.A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerCancer Chemotherapy and Pharmacology200964477778310.1007/s00280-009-0927-72-s2.0-6814916426319169683 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="465" pm="."><plain>93JensenL. </plain></SENT>
<SENT sid="466" pm="."><plain>H.LindebjergJ.PloenJ.HansenT. </plain></SENT>
<SENT sid="467" pm="."><plain>F.JakobsenA.Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancerAnnals of Oncology20122392341234610.1093/annonc/mds0082-s2.0-8486371952822367707 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="468" pm="."><plain>94MalkaD.CerveraP.FoulonS.Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialThe Lancet Oncology20141581982810.1016/s1470-2045(14)70212-82-s2.0-8490035260724852116 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="469" pm="."><plain>95YiJ. </plain></SENT>
<SENT sid="470" pm="."><plain>H.ThongprasertS.LeeJ.A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational studyEuropean Journal of Cancer201248219620110.1016/j.ejca.2011.11.0172-s2.0-8465516196422176869 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="471" pm="."><plain>96ZhuA. </plain></SENT>
<SENT sid="472" pm="."><plain>X.MeyerhardtJ. </plain></SENT>
<SENT sid="473" pm="."><plain>A.BlaszkowskyL. </plain></SENT>
<SENT sid="474" pm="."><plain>S.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyThe Lancet Oncology2010111485410.1016/s1470-2045(09)70333-x2-s2.0-7324912845119932054 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="475" pm="."><plain>97SiaD.TovarV.MoeiniA.LlovetJ. </plain></SENT>
<SENT sid="476" pm="."><plain>M.Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesOncogene201332414861487010.1038/onc.2012.6172-s2.0-8487523748123318457 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="477" pm="."><plain>98ShinoharaE. </plain></SENT>
<SENT sid="478" pm="."><plain>T.MitraN.GuoM.MetzJ. </plain></SENT>
<SENT sid="479" pm="."><plain>M.Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinomaInternational Journal of Radiation Oncology Biology Physics20087251495150110.1016/j.ijrobp.2008.03.0182-s2.0-56349116313 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="480" pm="."><plain>99ZengZ.-C.TangZ.-Y.FanJ.Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patientsCancer Journal20061221131222-s2.0-33645865522 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="481" pm="."><plain>100Ben-JosefE.NormolleD.EnsmingerW. </plain></SENT>
<SENT sid="482" pm="."><plain>D.Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignanciesJournal of Clinical Oncology200523348739874710.1200/JCO.2005.01.53542-s2.0-3364483394816314634 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="483" pm="."><plain>101BarneyB. </plain></SENT>
<SENT sid="484" pm="."><plain>M.OlivierK. </plain></SENT>
<SENT sid="485" pm="."><plain>R.MillerR. </plain></SENT>
<SENT sid="486" pm="."><plain>C.HaddockM. </plain></SENT>
<SENT sid="487" pm="."><plain>G.Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinomaRadiation Oncology201271, article 6710.1186/1748-717x-7-672-s2.0-84860360832 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="488" pm="."><plain>102Al-AdraD.GillR.AxfordS.ShiX.KnetemanN.LiauS.Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysisEuropean Journal of Surgical Oncology201541112012710.1016/j.ejso.2014.09.00725449754 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="489" pm="."><plain>103HyderO.MarshJ. </plain></SENT>
<SENT sid="490" pm="."><plain>W.SalemR.Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysisAnnals of Surgical Oncology201320123779378610.1245/s10434-013-3127-y2-s2.0-8488609958623846786 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="491" pm="."><plain>104HiraiK.KawazoeY.YamashitaK.Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinomaCancer Chemotherapy and Pharmacology1989231, supplementS37S4110.1007/bf006472372-s2.0-00245505722538264 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="492" pm="."><plain>105PattY. </plain></SENT>
<SENT sid="493" pm="."><plain>Z.ChuangV. </plain></SENT>
<SENT sid="494" pm="."><plain>P.WallaceS.BenjaminR. </plain></SENT>
<SENT sid="495" pm="."><plain>S.FuquaR.MavligitG. </plain></SENT>
<SENT sid="496" pm="."><plain>M.Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liverCancer19835181359136310.1002/1097-0142(19830415)51:8&amp;lt;1359::AID-CNCR2820510807&gt;3.0.CO;2-V2-s2.0-00207009536186357 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="497" pm="."><plain>106SasakiY.ImaokaS.KasugaiH.A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin spongeCancer19876061194120310.1002/1097-0142(19870915)60:660;1194::aid-cncr282060060762;3.0.co;2-t2-s2.0-00236298112441837 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="498" pm="."><plain>107LlovetJ. </plain></SENT>
<SENT sid="499" pm="."><plain>M.RealM. </plain></SENT>
<SENT sid="500" pm="."><plain>I.MontañaX.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet200235993191734173910.1016/s0140-6736(02)08649-x2-s2.0-0037129704 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="501" pm="."><plain>108LoC.-M.NganH.TsoW.-K.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology20023551164117110.1053/jhep.2002.331562-s2.0-003623782211981766 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="502" pm="."><plain>109BurgerI.HongK.SchulickR.Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institutionJournal of Vascular and Interventional Radiology200516335336110.1097/01.rvi.0000143768.60751.782-s2.0-1484434357015758131 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="503" pm="."><plain>110GusaniN. </plain></SENT>
<SENT sid="504" pm="."><plain>J.BalaaF. </plain></SENT>
<SENT sid="505" pm="."><plain>K.SteelJ. </plain></SENT>
<SENT sid="506" pm="."><plain>L.Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experienceJournal of Gastrointestinal Surgery200812112913710.1007/s11605-007-0312-y2-s2.0-3814900152017851723 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="507" pm="."><plain>111CarrafielloG.LaganàD.CottaE.Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experienceCardioVascular and Interventional Radiology201033483583910.1007/s00270-010-9849-32-s2.0-7795618495420411389 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="508" pm="."><plain>112ChiouY.-Y.HwangJ.-I.ChouY.-H.WangH.-K.ChiangJ.-H.ChangC.-Y.Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinomaThe Kaohsiung Journal of Medical Sciences200521730430910.1016/s1607-551x(09)70125-12-s2.0-2304446610616089307 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="509" pm="."><plain>113FuY.YangW.WuW.YanK.XingB. </plain></SENT>
<SENT sid="510" pm="."><plain>C.ChenM. </plain></SENT>
<SENT sid="511" pm="."><plain>H.Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinomaJournal of Vascular and Interventional Radiology201223564264910.1016/j.jvir.2012.01.0812-s2.0-8486023110122525022 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="512" pm="."><plain>114GiorgioA.CalistiG.de StefanoG.Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experienceAnticancer Research20113112457545802-s2.0-8485517410122199333 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="513" pm="."><plain>115HaiduM.DobrozemskyG.SchullianP.Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective studyCardioVascular and Interventional Radiology20123551074108210.1007/s00270-011-0288-62-s2.0-8486757285922006031 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="514" pm="."><plain>116KimJ. </plain></SENT>
<SENT sid="515" pm="."><plain>H.WonH. </plain></SENT>
<SENT sid="516" pm="."><plain>J.ShinY. </plain></SENT>
<SENT sid="517" pm="."><plain>M.KimK.-A.KimP. </plain></SENT>
<SENT sid="518" pm="."><plain>N.Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinomaAmerican Journal of Roentgenology20111962W205W20910.2214/AJR.10.49372-s2.0-7925150031321257864 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="519" pm="."><plain>117KimJ. </plain></SENT>
<SENT sid="520" pm="."><plain>H.WonH. </plain></SENT>
<SENT sid="521" pm="."><plain>J.ShinY. </plain></SENT>
<SENT sid="522" pm="."><plain>M.KimP. </plain></SENT>
<SENT sid="523" pm="."><plain>N.LeeS.-G.HwangS.Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resectionEuropean Journal of Radiology2011803e221e22510.1016/j.ejrad.2010.09.0192-s2.0-8075515232620950977 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="524" pm="."><plain>118Darwish MuradS.KimW. </plain></SENT>
<SENT sid="525" pm="."><plain>R.HarnoisD. </plain></SENT>
<SENT sid="526" pm="."><plain>M.Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centersGastroenterology201214388.e398.e3, e1422504095 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="527" pm="."><plain>119HongJ. </plain></SENT>
<SENT sid="528" pm="."><plain>C.JonesC. </plain></SENT>
<SENT sid="529" pm="."><plain>M.DuffyJ. </plain></SENT>
<SENT sid="530" pm="."><plain>P.Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single centerArchives of Surgery2011146668368910.1001/archsurg.2011.1162-s2.0-7995934268321690444 </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="531" pm="."><plain>120HuX.-X.YanL.-N.Retrospective analysis of prognostic factors after liver transplantation for intrahepatic cholangiocarcinoma in China: a single-center experienceHepato-Gastroenterology2011581091255125910.5754/hge107042-s2.0-8335516505921937390 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="532" pm="."><plain>121SapisochinG.Rodríguez De LopeC.GastacaM.‘Very early’ intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?American Journal of Transplantation201414366066710.1111/ajt.125912-s2.0-8489670231524410861 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="533" pm="."><plain>Treatment algorithm for intrahepatic cholangiocarcinoma. </plain></SENT>
</text></p></caption><graphic xlink:href="GRP2015-860861.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="534" pm="."><plain>MRI and pathologic correlation of intrahepatic cholangiocarcinoma. </plain></SENT>
<SENT sid="535" pm="."><plain>(a) Yellow-grey intrahepatic mass on pathologic specimen. </plain></SENT>
<SENT sid="536" pm="."><plain>(b) Portal venous phase MRI of intrahepatic cholangiocarcinoma designated by box with hypointense lesion. </plain></SENT>
<SENT sid="537" pm="."><plain>(c) Delayed contrast-enhanced MRI of the same lesion showing accumulation of contrast within the lesion. </plain></SENT>
<SENT sid="538" pm="."><plain>Reprinted from Cancer Imaging [42]. </plain></SENT>
</text></p></caption><graphic xlink:href="GRP2015-860861.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="539" pm="."><plain>Signaling pathways involved in intrahepatic cholangiocarcinoma and the corresponding molecular therapies. </plain></SENT>
<SENT sid="540" pm="."><plain>Reprinted from McMilan Publishers Ltd.: Oncogene [97]. </plain></SENT>
</text></p></caption><graphic xlink:href="GRP2015-860861.003"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="541" pm="."><plain>Risk factors for cholangiocarcinoma. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>General risk factors </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>Inflammatory risk factors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain> Obesity </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="545" pm="."><plain> Primary sclerosing cholangitis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain> Tobacco use </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain> Hepatolithiasis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain> Age &gt; 65 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain> Biliary cirrhosis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain> Type II diabetes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="551" pm="."><plain> Inflammatory bowel disease </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain> Excessive alcohol intake </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain> Biliary-enteric anastomosis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain> NAFLD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>Parasitic risk factors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>Congenital risk factors </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="557" pm="."><plain>  Clonorchis sinensis  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain> Caroli's disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>  Opisthorchis viverrini  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain> Choledochal cysts </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>Chemical risk factors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain> Congenital hepatic fibrosis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain> Nitrosamines </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain> Bile duct adenomas </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain> Vinyl chloride </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain> Biliary papillomatosis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain> Thorotrast </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>Viral risk factors </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain> Dioxin </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain> Hepatitis B </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain> Oral contraceptives </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="572" pm="."><plain> Hepatitis C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="573" pm="."><plain> Isoniazid </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain> HIV </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain> Asbestos </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>  </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain> Radon </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="578" pm="."><plain>American Joint Committee on Cancer (AJCC). </plain></SENT>
<SENT sid="579" pm="."><plain>TNM Staging for Intrahepatic Bile Duct Tumors (7th edition, 2010). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="580" pm="."><plain>Primary tumor (T) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="581" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="582" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="583" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="584" pm="."><plain>TX </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="585" pm="."><plain>Primary tumor cannot be assessed </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="586" pm="."><plain>T0 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="587" pm="."><plain>No evidence of primary tumor </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="588" pm="."><plain>Tis </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="589" pm="."><plain>Carcinoma in situ (intraductal tumor) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="590" pm="."><plain>T1 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="591" pm="."><plain>Solitary tumor without vascular invasion </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="592" pm="."><plain>T2a </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="593" pm="."><plain>Solitary tumor with vascular invasion </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="594" pm="."><plain>T2b </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="595" pm="."><plain>Multiple tumors, with or without vascular invasion </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="596" pm="."><plain>T3 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="597" pm="."><plain>Tumor perforating the visceral peritoneum or involving the </plain></SENT>
</text></td></tr><tr><td align="left" colspan="3" rowspan="1"><text><SENT sid="598" pm="."><plain>Local extra hepatic structures by direct invasion T4 Tumor with periductal invasion </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="599" pm="."><plain>Regional lymph nodes (N) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="600" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="601" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="602" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="603" pm="."><plain> NX </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="604" pm="."><plain>Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="605" pm="."><plain> N1 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="606" pm="."><plain>Regional lymph node metastasis present </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="607" pm="."><plain>Distant metastasis (M) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="608" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="609" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="610" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="611" pm="."><plain> M0 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="612" pm="."><plain>No distant metastasis </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="613" pm="."><plain> M1 </plain></SENT>
</text></td><td align="left" colspan="3" rowspan="1"><text><SENT sid="614" pm="."><plain>Distant metastasis present </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="615" pm="."><plain>Anatomic stage groupings </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="616" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="617" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="618" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="619" pm="."><plain> Stage 0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="620" pm="."><plain>Tis </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="621" pm="."><plain>N0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="622" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="623" pm="."><plain> Stage I </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="624" pm="."><plain>T1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="625" pm="."><plain>N0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="626" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="627" pm="."><plain> Stage II </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="628" pm="."><plain>T2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="629" pm="."><plain>N0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="630" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="631" pm="."><plain> Stage III </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="632" pm="."><plain>T3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="633" pm="."><plain>N0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="634" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="2" colspan="1"><text><SENT sid="635" pm="."><plain> Stage IVA </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="636" pm="."><plain>T4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="637" pm="."><plain>N0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="638" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="639" pm="."><plain>Any T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="640" pm="."><plain>N1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="641" pm="."><plain>M0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="642" pm="."><plain> Stage IVB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="643" pm="."><plain>Any T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="644" pm="."><plain>Any N </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="645" pm="."><plain>M1 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></floats-group></article>
